Analyst Reco. IDEAYA Biosciences, Inc.

Equities

IDYA

US45166A1025

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
40.65 ^USD	+1.78%		+4.18%	+14.25%

Apr. 22	IDEAYA Biosciences Selects Move-Forward Expansion Dose for Mid-Stage Trial of IDE397 Monotherapy	MT
Apr. 22	IDEAYA Biosciences, Inc. Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Citigroup Raises IDEAYA Biosciences' Price Target to $60 From $40, Maintains Buy Rating	Mar. 21	MT
BTIG Starts Coverage on IDEAYA Biosciences With Buy Rating, $55 Price Target	Mar. 08	MT
RBC Raises Price Target on IDEAYA Biosciences to $53 From $43 on 'Clarity & Confidence on Daro's Potential,' Keeps Outperform Rating, Speculative Risk	Feb. 21	MT
Wedbush Raises IDEAYA Biosciences' PT to $52 From $46, Updates Model to Include Recent Financings; Keeps Outperform Rating	Feb. 20	MT
Goldman Sachs Adjusts Price Target on IDEAYA Biosciences to $53 From $36, Maintains Buy Rating	Jan. 25	MT
Wedbush Raises Price Target on IDEAYA Biosciences to $46 From $43, Maintains Outperform Rating	Jan. 16	MT
RBC Adjusts IDEAYA Biosciences' Price Target to $43 From $36, Keeps Outperform Rating	Jan. 10	MT
JPMorgan Raises IDEAYA Biosciences' Price Target to $35 From $32, Maintains Overweight Rating	23-10-24	MT
RBC Raises Price Target on IDEAYA Biosciences to $36 From $32, Keeps Outperform Rating, Speculative Risk Qualifier	23-10-24	MT
Wedbush Lifts Ideaya Biosciences' Price Target to $43 From $40 After Phase 1 Study of Novel PARG Inhibitor IDE16 Early Results, Keeps Outperform Rating	23-09-12	MT
Goldman Sachs Adjusts IDEAYA Biosciences' Price Target to $37 From $31, Keeps Buy Rating	23-09-12	MT
Wedbush Lifts Ideaya Biosciences' Price Target to $43 From $40, Keeps Outperform Rating	23-09-12	MT
JPMorgan Chase Raises Price Target on IDEAYA Biosciences to $32 From $28, Maintains Overweight Rating	23-08-17	MT
Oppenheimer Adjusts IDEAYA Biosciences Price Target to $35 From $30, Maintains Outperform Rating	23-08-11	MT
RBC Raises Price Target on IDEAYA Biosciences to $32 From $30, Maintains Outperform Rating, Speculative Risk Qualifier	23-08-11	MT
Wedbush Raises IDEAYA Biosciences' PT to $40 From $35 on Increased Confidence in IDE397/AMG 193 Combination, Keeps Outperform Rating	23-08-11	MT
SVB Securities Initiates IDEAYA Biosciences With Outperform Rating, $33 Price Target	23-08-08	MT
Wedbush Trims Foghorn Therapeutics Price Target to $13 From $14, Maintains Outperform Rating	23-06-28	MT
Goldman Sachs Initiates IDEAYA Biosciences at Buy With $32 Price Target	23-05-24	MT
Wedbush Adjusts Price Target on IDEAYA Biosciences to $35 From $30, Maintains Outperform Rating	23-04-24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. IDEAYA Biosciences, Inc.

Equities

IDYA

US45166A1025

Analyst Reco.

Filters